Trials / Suspended
SuspendedNCT00226109
Clinical Trial Studying the Effects of Spironolactone on Heart and Skeletal Muscle Function in Chronic Alcoholics
Effect of Spironolactone Treatment on Heart- and Skeletal Muscle in Chronic Alcoholics
- Status
- Suspended
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- University of Aarhus · Academic / Other
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Chronic alcoholics suffer from weak skeletal and cardiac muscle. The investigators have discovered a beneficial effect of spironolactone-treatment in that regard. Therefore, a double blind placebo controlled study is conducted, to examine the effects of spironolactone on cardiac and skeletal muscle-function in chronic alcoholics.
Detailed description
Our department has done research into skeletal muscle function in patients with liver cirrhosis. Post-hoc analyses of one of these studies suggested that treatment with spironolactone had a positive effect on muscle strength and endurance. This effect was probably caused by an increase in concentration of Na, K-pumps (sodium-potassium pumps) enabling the muscle cell perform better. To verify this finding we have designed a double-blinded, placebo-controlled, randomized clinical trial with skeletal muscle strength, -endurance, Na, K-pump content, cardiac systolic, and diastolic function as primary endpoints. Spironolactone is tested against placebo in 40 participants included among our admitted and out-clinic patients. Muscle function-tests, muscle biopsy and trans-thoracic echocardiography is performed before and after 12 weeks of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | spironolactone | 100 mg once daily. Can be reduced to 50 mg a day still maintaining the doubled-blinded status |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2011-08-01
- Completion
- 2011-12-01
- First posted
- 2005-09-26
- Last updated
- 2010-10-20
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT00226109. Inclusion in this directory is not an endorsement.